Explore the latest FDA & China-approved drugs in June 2025, including Genakumab (gout), Taletrectinib (NSCLC), and Clesrovimab (RSV). Key clinical benefits & market impact.

Explore how CSPC ($5B deal), Sanofi, and Eli Lilly invested $12B+ in AI drug discovery, RNA editing & in vivo CAR-T in May 2025.

In May 2025, the global pharmaceutical landscape witnessed a wave of innovation.

In April 2025, a series of innovative drugs targeting various disease areas received regulatory approval, ranging from rare diseases.

Explore the booming mRNA therapeutics market, projected to exceed USD 100 billion by 2028. Learn how mRNA drugs work, their key advantages, and the global leaders driving innovation in vaccines and cancer treatment.

Nav1.8 inhibitors represent a breakthrough in pain therapeutics, offering a non-addictive alternative to opioids.

Explore the safety challenges of ASO drugs, and learn how chemical modifications and targeted delivery strategies can mitigate risks while preserving therapeutic efficacy in precision medicine.

This article reviews the biological mechanisms of FGFR dysregulation and clinical advances of FGFR inhibitors like erdafitinib in treating urothelial carcinoma and other malignancies with FGFR alterations.

Explore major breakthroughs in antibody-drug conjugates (ADCs) in 2024, including key targets like Trop-2, HER2, EGFR, and c-Met. Learn about landmark drug approvals, late-stage clinical trials, and the future of precision cancer therapy.

B7-H3 (CD276), a type I transmembrane glycoprotein, has garnered significant attention due to its overexpression in a wide range of human cancers.

A landmark ruling by Japan’s IP High Court awarded record-breaking $150 million damages in the Nalfurafine (Remitch®) patent dispute. This case reshapes how pharmaceutical companies approach patent term extensions, generic entry strategies, and IP litigation risks.

YS2302018 was discovered by CSPC and has been shown to effectively prevent the formation of Lp(a).